The Institute of Cancer Research at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
The Institute of Cancer Research takes part in 7 sessions at ESMO 2026 in Madrid. Its program centres on Claudin 18.2-targeted therapy and precision medicine in gastric and gastroesophageal junction adenocarcinoma. Other sessions cover cellular therapy in solid tumours, cancer vaccines for colorectal cancer, PARP inhibitors in triple-negative breast cancer, the tumour microenvironment and radiotherapy for penile cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
The Institute of Cancer Research London, United Kingdom | |
Cancer research institute and college of the University of London, partnered with The Royal Marsden, a specialist cancer hospital in London. | Satellite Fri Oct 23 18:35–18:45 Selecting your piece: CLDN18.2 targeted therapies Gastrointestinal cancers Satellite Fri Oct 23 18:55–19:10 The emerging picture: Precision medicine in clinical decision-making Gastrointestinal cancers Satellite Fri Oct 23 19:10–19:20 Every piece matters: Maximising patient outcomes Gastrointestinal cancers Satellite Fri Oct 23 19:20–19:40 The complete picture: Enhancing patient care Gastrointestinal cancers Chair Sat Oct 24 08:30–10:00 Talk Sat Oct 24 09:15–09:30 Anti-cancer vaccines: Technologies and clinical applications Gastrointestinal cancers Talk Sat Oct 24 15:25–15:45 Incorporation of PARP inhibitors Breast cancer Talk Sun Oct 25 11:00–11:15 Abstract Mon Oct 26 08:30–08:35 3717RO - Phase 3 Peak Crossover: Bezuclastinib + Sunitinib Combination Following Sunitinib Monotherapy in Patients with GIST Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 15:20–15:40 |
Instantly find 20 buyers from The Institute of Cancer Research
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction